Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder
The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with l...
Gespeichert in:
| Veröffentlicht in: | Proteomics (Weinheim) 2011-01, Vol.11 (2), p.261-269 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Proteomics (Weinheim) |
| container_volume | 11 |
| creator | Sussulini, Alessandra Dihazi, Hassan Banzato, Claudio Eduardo Muller Arruda, Marco Aurelio Zezzi Stühmer, Walter Ehrenreich, Hannelore Jahn, Olaf Kratzin, Hartmut D |
| description | The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level. |
| doi_str_mv | 10.1002/pmic.201000371 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_883021420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>883021420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5621-74c2c27dac6a60f1ee9a01fa5d75dfe2a88615faa723443ff3c18879aeeba2e93</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxSMEoqVw5QiWKsQpiz_iODmuVlBWLB9SKeVmzTpj1iWJg50I-t_jVZYFcenJc_i9N_P8suwpowtGKX81dM4sOE0zFYrdy05ZyWReVyW7f5ylOMkexXhDKVNVrR5mJ5xxWnApTrPdcvCtG_wQ_IiuJ8t8TSASIAb6xjUwIokYpo50EL5jINYHMu6QBIyD7yOS0ZPWjTuXkDEgjB32I0lG22TaQiCNiz40GB5nDyy0EZ8c3rPs6s3rz6u3-ebjxXq13ORGlpzlqjDccNWAKaGkliHWQJkF2SjZWORQpWjSAiguikJYKwyrKlUD4hY41uIsezn7pkQ_Joyj7lw02LbQo5-iripBOSs4vZvkXMpSqT15_h9546fQpxiaSaaKgnFWJmoxUyb4GANaPQSXvu1WM6r3Zel9WfpYVhI8O9hO2w6bI_6nnQS8OAAQDbQ2QG9c_MsJVaS9KnH1zP10Ld7esVZ_er9e_XtEPmtdHPHXUZva1qUSSurrDxf6K_1yuXlXXet9yuczb8Fr-BbSPVeXyU5QVgtWF1T8Bgtnxf8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1517441216</pqid></control><display><type>article</type><title>Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder</title><source>MEDLINE</source><source>Wiley Blackwell Journals</source><creator>Sussulini, Alessandra ; Dihazi, Hassan ; Banzato, Claudio Eduardo Muller ; Arruda, Marco Aurelio Zezzi ; Stühmer, Walter ; Ehrenreich, Hannelore ; Jahn, Olaf ; Kratzin, Hartmut D</creator><creatorcontrib>Sussulini, Alessandra ; Dihazi, Hassan ; Banzato, Claudio Eduardo Muller ; Arruda, Marco Aurelio Zezzi ; Stühmer, Walter ; Ehrenreich, Hannelore ; Jahn, Olaf ; Kratzin, Hartmut D</creatorcontrib><description>The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level.</description><identifier>ISSN: 1615-9853</identifier><identifier>ISSN: 1615-9861</identifier><identifier>EISSN: 1615-9861</identifier><identifier>DOI: 10.1002/pmic.201000371</identifier><identifier>PMID: 21204253</identifier><language>eng</language><publisher>Weinheim: Wiley-VCH Verlag</publisher><subject>Adult ; Adult and adolescent clinical studies ; Amino Acid Sequence ; Analytical, structural and metabolic biochemistry ; Antipsychotic Agents - therapeutic use ; Apolipoprotein A-I ; Apolipoprotein A-I - blood ; Apolipoproteins ; Biological and medical sciences ; Biomarker ; Biomarkers - blood ; Biomedicine ; Bipolar disorder ; Bipolar Disorder - diagnosis ; Bipolar Disorder - drug therapy ; Bipolar disorders ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Language disorders ; Lithium ; Lithium Compounds - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Molecular Sequence Data ; Mood disorders ; Proteins ; Proteome - metabolism ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Serum ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><ispartof>Proteomics (Weinheim), 2011-01, Vol.11 (2), p.261-269</ispartof><rights>Copyright © 2011 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><rights>Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5621-74c2c27dac6a60f1ee9a01fa5d75dfe2a88615faa723443ff3c18879aeeba2e93</citedby><cites>FETCH-LOGICAL-c5621-74c2c27dac6a60f1ee9a01fa5d75dfe2a88615faa723443ff3c18879aeeba2e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpmic.201000371$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpmic.201000371$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23741637$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21204253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sussulini, Alessandra</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Banzato, Claudio Eduardo Muller</creatorcontrib><creatorcontrib>Arruda, Marco Aurelio Zezzi</creatorcontrib><creatorcontrib>Stühmer, Walter</creatorcontrib><creatorcontrib>Ehrenreich, Hannelore</creatorcontrib><creatorcontrib>Jahn, Olaf</creatorcontrib><creatorcontrib>Kratzin, Hartmut D</creatorcontrib><title>Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder</title><title>Proteomics (Weinheim)</title><addtitle>Proteomics</addtitle><description>The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Amino Acid Sequence</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Apolipoprotein A-I</subject><subject>Apolipoprotein A-I - blood</subject><subject>Apolipoproteins</subject><subject>Biological and medical sciences</subject><subject>Biomarker</subject><subject>Biomarkers - blood</subject><subject>Biomedicine</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - diagnosis</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Bipolar disorders</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Language disorders</subject><subject>Lithium</subject><subject>Lithium Compounds - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Molecular Sequence Data</subject><subject>Mood disorders</subject><subject>Proteins</subject><subject>Proteome - metabolism</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Serum</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><issn>1615-9853</issn><issn>1615-9861</issn><issn>1615-9861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAQxSMEoqVw5QiWKsQpiz_iODmuVlBWLB9SKeVmzTpj1iWJg50I-t_jVZYFcenJc_i9N_P8suwpowtGKX81dM4sOE0zFYrdy05ZyWReVyW7f5ylOMkexXhDKVNVrR5mJ5xxWnApTrPdcvCtG_wQ_IiuJ8t8TSASIAb6xjUwIokYpo50EL5jINYHMu6QBIyD7yOS0ZPWjTuXkDEgjB32I0lG22TaQiCNiz40GB5nDyy0EZ8c3rPs6s3rz6u3-ebjxXq13ORGlpzlqjDccNWAKaGkliHWQJkF2SjZWORQpWjSAiguikJYKwyrKlUD4hY41uIsezn7pkQ_Joyj7lw02LbQo5-iripBOSs4vZvkXMpSqT15_h9546fQpxiaSaaKgnFWJmoxUyb4GANaPQSXvu1WM6r3Zel9WfpYVhI8O9hO2w6bI_6nnQS8OAAQDbQ2QG9c_MsJVaS9KnH1zP10Ld7esVZ_er9e_XtEPmtdHPHXUZva1qUSSurrDxf6K_1yuXlXXet9yuczb8Fr-BbSPVeXyU5QVgtWF1T8Bgtnxf8</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Sussulini, Alessandra</creator><creator>Dihazi, Hassan</creator><creator>Banzato, Claudio Eduardo Muller</creator><creator>Arruda, Marco Aurelio Zezzi</creator><creator>Stühmer, Walter</creator><creator>Ehrenreich, Hannelore</creator><creator>Jahn, Olaf</creator><creator>Kratzin, Hartmut D</creator><general>Wiley-VCH Verlag</general><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><general>Wiley-VCH</general><general>Wiley Subscription Services, Inc</general><scope>FBQ</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder</title><author>Sussulini, Alessandra ; Dihazi, Hassan ; Banzato, Claudio Eduardo Muller ; Arruda, Marco Aurelio Zezzi ; Stühmer, Walter ; Ehrenreich, Hannelore ; Jahn, Olaf ; Kratzin, Hartmut D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5621-74c2c27dac6a60f1ee9a01fa5d75dfe2a88615faa723443ff3c18879aeeba2e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Amino Acid Sequence</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Apolipoprotein A-I</topic><topic>Apolipoprotein A-I - blood</topic><topic>Apolipoproteins</topic><topic>Biological and medical sciences</topic><topic>Biomarker</topic><topic>Biomarkers - blood</topic><topic>Biomedicine</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - diagnosis</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Bipolar disorders</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Language disorders</topic><topic>Lithium</topic><topic>Lithium Compounds - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Molecular Sequence Data</topic><topic>Mood disorders</topic><topic>Proteins</topic><topic>Proteome - metabolism</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Serum</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sussulini, Alessandra</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Banzato, Claudio Eduardo Muller</creatorcontrib><creatorcontrib>Arruda, Marco Aurelio Zezzi</creatorcontrib><creatorcontrib>Stühmer, Walter</creatorcontrib><creatorcontrib>Ehrenreich, Hannelore</creatorcontrib><creatorcontrib>Jahn, Olaf</creatorcontrib><creatorcontrib>Kratzin, Hartmut D</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Proteomics (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sussulini, Alessandra</au><au>Dihazi, Hassan</au><au>Banzato, Claudio Eduardo Muller</au><au>Arruda, Marco Aurelio Zezzi</au><au>Stühmer, Walter</au><au>Ehrenreich, Hannelore</au><au>Jahn, Olaf</au><au>Kratzin, Hartmut D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder</atitle><jtitle>Proteomics (Weinheim)</jtitle><addtitle>Proteomics</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>11</volume><issue>2</issue><spage>261</spage><epage>269</epage><pages>261-269</pages><issn>1615-9853</issn><issn>1615-9861</issn><eissn>1615-9861</eissn><abstract>The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level.</abstract><cop>Weinheim</cop><pub>Wiley-VCH Verlag</pub><pmid>21204253</pmid><doi>10.1002/pmic.201000371</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1615-9853 |
| ispartof | Proteomics (Weinheim), 2011-01, Vol.11 (2), p.261-269 |
| issn | 1615-9853 1615-9861 1615-9861 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_883021420 |
| source | MEDLINE; Wiley Blackwell Journals |
| subjects | Adult Adult and adolescent clinical studies Amino Acid Sequence Analytical, structural and metabolic biochemistry Antipsychotic Agents - therapeutic use Apolipoprotein A-I Apolipoprotein A-I - blood Apolipoproteins Biological and medical sciences Biomarker Biomarkers - blood Biomedicine Bipolar disorder Bipolar Disorder - diagnosis Bipolar Disorder - drug therapy Bipolar disorders Female Fundamental and applied biological sciences. Psychology Humans Language disorders Lithium Lithium Compounds - therapeutic use Male Medical sciences Middle Aged Miscellaneous Molecular Sequence Data Mood disorders Proteins Proteome - metabolism Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Serum Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| title | Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A11%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apolipoprotein%20A-I%20as%20a%20candidate%20serum%20marker%20for%20the%20response%20to%20lithium%20treatment%20in%20bipolar%20disorder&rft.jtitle=Proteomics%20(Weinheim)&rft.au=Sussulini,%20Alessandra&rft.date=2011-01-01&rft.volume=11&rft.issue=2&rft.spage=261&rft.epage=269&rft.pages=261-269&rft.issn=1615-9853&rft.eissn=1615-9861&rft_id=info:doi/10.1002/pmic.201000371&rft_dat=%3Cproquest_cross%3E883021420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1517441216&rft_id=info:pmid/21204253&rfr_iscdi=true |